Zidesamtinib is a small molecule commercialized by Nuvalent, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Zidesamtinibs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zidesamtinib is expected to reach an annual total of $61 mn by 2035 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zidesamtinib Overview
NVL-520 is under development for the treatment of ROS1 positive non-small cell lung cancer, other advanced solid tumors and glioblastoma multiforme. It is administered through oral route in the form of film-coated tablets. The drug candidate acts by targeting proto oncogene tyrosine protein kinase (ROS1).
Nuvalent Overview
Nuvalent is a clinical-stage biopharmaceutical company that develops innovative small molecules for cancer. The companys pipeline products include zidesamtinib (NVL-520) a ROS1-selective inhibitor; NVL-655 a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor; NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor. Its lead candidates treat solid tumors, non-small cell lung cancer (NSCLC) and brain metastases. The company works in collaboration with contract research organizations (CROs), medical institutions and contract manufacturing organizations (CMOs) to conduct and support preclinical studies and clinical trials. Nuvalent is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$149.5 million in FY2023, compared to an operating loss of US$86.1 million in FY2022. The net loss of the company was US$126.2 million in FY2023, compared to a net loss of US$81.9 million in FY2022.
For a complete picture of Zidesamtinibs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.